ABCL vs TMUS · rev $12.4M vs P/E 19, rev $22.79B
Abcellera Biologics Inc (ABCL) versus T-Mobile US Inc (TMUS) — a side-by-side from cached financials, not a winner call.
Abcellera Biologics Inc (ABCL) is a biotechnology company listed on US.
T-Mobile US Inc (TMUS) is a telecom services company listed on NASDAQ. It is led by Mike Sievert.
Latest reported ABCL revenue for 2026-06-30 was $12.4M. Net income was -$98.6M. Revenue was up 48.7% from 2026-03-31 to 2026-06-30. ABCL currently screens at market cap $1.12B.
Latest reported TMUS revenue for 2026-06-30 was $22.79B. Net income was $3.24B. Revenue was down 1.4% from 2026-03-31 to 2026-06-30. TMUS currently screens at market cap $196.21B and trailing P/E 19.3.
ABCL currently screens at market cap $1.12B. TMUS currently screens at market cap $196.21B and trailing P/E 19.3.
Not investment advice. Open the ABCL and TMUS stock pages for the full models.
Not investment advice.